Hematopoietic cytokines in the sera of patients with pancreatic cancer.

Clin Chem Lab Med

Department of Biochemical Diagnostics, Medical Academy, Bialystok, Poland.

Published: August 2005

AI Article Synopsis

  • The study explored the serum levels of hematopoietic cytokines (HCs) in pancreatic cancer patients compared to those with chronic pancreatitis and healthy subjects.
  • Key findings indicated significant differences in levels of specific cytokines (SCF, IL-3, GM-CSF, M-CSF) and tumor markers (CEA, CA 19-9) among groups, with correlations to tumor stage.
  • The research suggested that certain HCs, particularly SCF and M-CSF, may be useful in the detection of pancreatic cancer, warranting further investigation for early-stage cases.

Article Abstract

Hematopoietic cytokines (HCs) can affect the growth and spread of cancer. Therefore, in the present study, we investigated in pancreatic cancer patients the serum levels of selected HCs, such as stem cell factor (SCF), interleukin 3 (IL-3), granulocyte-macrophage-colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF) in relation to a control group and to a group of patients with chronic pancreatitis. Classical tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) were also tested. We compared the serum level of cytokines with the tumor stage. The diagnostic sensitivity, specificity, positive and negative predictive values and receiver-operating characteristics (ROC) curve for cytokines and classical tumor markers were defined. The cytokines were measured in 48 patients with pancreatic cancer, in 23 patients with chronic pancreatitis and in 40 healthy subjects. HCs were determined using ELISA. CEA and CA 19-9 were measured by microparticle enzyme immunoassay. There were significant differences in the levels of circulating SCF, IL-3, GM-CSF, M-CSF, CEA and CA 19-9 in the pancreatic cancer patients compared to the control group. The serum levels of M-CSF and tumor markers were significantly higher in pancreatic cancer patients compared to the pancreatitis group. The levels of SCF, M-CSF and tumor markers were higher in patients with a more advanced tumor stage. The M-CSF serum levels in the pancreatitis group correlated positively with the tumor markers tested--CEA and CA 19-9. The diagnostic sensitivity of SCF and specificity of M-CSF and tumor markers were the highest. The SCF and M-CSF areas under the ROC curve were greater than the areas for other cytokines. These results suggest the potential usefulness of HCs in pancreatic cancer detection; however, further investigations of early-stage pancreatic cancer patients and confirmation by a prospective study are necessary.

Download full-text PDF

Source
http://dx.doi.org/10.1515/CCLM.2005.024DOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
28
tumor markers
24
cancer patients
20
serum levels
12
stimulating factor
12
m-csf tumor
12
patients
9
hematopoietic cytokines
8
patients pancreatic
8
cancer
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!